| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| eft508 | mapk signal-integrating kinase 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] Liver carcinoma[MeSHID:D006528] Malignant Neoplasms[MeSHID:D009369] Triple Negative Breast Neoplasms[MeSHID:D064726] Colorectal Cancer[MeSHID:D015179] |
8.49 | phase 2 | unknown |
| eft508 | map kinase signal-integrating kinase 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] Liver carcinoma[MeSHID:D006528] Malignant Neoplasms[MeSHID:D009369] Triple Negative Breast Neoplasms[MeSHID:D064726] Colorectal Cancer[MeSHID:D015179] |
1.59 | phase 2 | unknown |
| click here to return to the previous page | ||||||||